Comparative Effectiveness: Managed Care Eager For Data, Including Cost
Executive Summary
Traditional studies, such as randomized controlled clinical trials, post-marketing surveillance and monitoring, and voluntary reporting systems are not providing enough information about efficacy and safety of medications for health plans to make informed decisions, said participants in a panel on comparative effectiveness at an Academy of Managed Care Pharmacy meeting in Orlando in April
You may also be interested in...
CMS Pay For Off-Label Use Of Avastin In Wet Age-Related Macular Degeneration May Discourage Use
Rate based on Avastin's cancer indication puts ophthalmologists in the position of choosing whether to take a loss to administer it to Medicare beneficiaries or get full reimbursement for the more expensive, FDA-approved Lucentis.
Lucentis Faces Additional Pressure From NIH’s Avastin Trials
Genentech could face difficulties enrolling trials for its ocular vascular endothelial growth factor inhibitor Lucentis due to pressure from NIH-sponsored trials of the firm's oncologic VEGF inhibitor Avastin
Making The Most Of ACOs: How Biopharma Is Adapting To New Customer Segment
ACOs have been one of the most hyped innovations in the US health care sector this decade. The buzz may be overdone, but ACOs are now established as a different—and confusing—new customer segment for pharma. How is industry adjusting?